HUTCHMED (China) Limited ( (HK:0013) ) has provided an update.
HUTCHMED announced that it will present new and updated data from several studies at the AACR Annual Meeting 2025, highlighting the progress of its compounds, including savolitinib, fruquintinib, and surufatinib. These presentations underscore HUTCHMED’s ongoing efforts to advance cancer treatment options and strengthen its position in the oncology field, potentially impacting its market presence and offering new hope for patients with various types of cancer.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery and development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company is involved in the development of compounds such as savolitinib, fruquintinib, and surufatinib, with a strong emphasis on addressing unmet medical needs in oncology, particularly in the Chinese market.
Average Trading Volume: 51,252
Technical Sentiment Signal: Buy
Current Market Cap: £2.09B
For detailed information about 0013 stock, go to TipRanks’ Stock Analysis page.